2022 - Research.com Microbiology in Switzerland Leader Award
2016 - Member of Academia Europaea
His primary areas of study are Immunology, Internal medicine, Acquired immunodeficiency syndrome, Cohort study and Virology. His is doing research in Viral load, Viral disease, T cell, Hepatitis C virus and Immune system, both of which are found in Immunology. Manuel Battegay has researched Internal medicine in several fields, including Gastroenterology, Surgery and Ritonavir.
His research in Acquired immunodeficiency syndrome tackles topics such as Risk factor which are related to areas like Physical therapy. His Cohort study research includes elements of Epidemiology, Confidence interval, Antiretroviral therapy, Prospective cohort study and Cohort. His Virology research is multidisciplinary, incorporating elements of Epitope, Antibody, CTL* and Lymphocytic choriomeningitis.
Manuel Battegay mainly investigates Internal medicine, Immunology, Cohort study, Virology and Acquired immunodeficiency syndrome. His research links Gastroenterology with Internal medicine. His study in Viral load, Viral disease, Immune system, Immunopathology and Hepatitis C virus is carried out as part of his studies in Immunology.
His work deals with themes such as Odds ratio, Incidence, Surgery, Antiretroviral therapy and Pediatrics, which intersect with Cohort study. The Virology study combines topics in areas such as Antibody and Antigen. His research in the fields of Sida overlaps with other disciplines such as Cart.
Manuel Battegay mostly deals with Internal medicine, Cohort study, Confidence interval, Viral load and Epidemiology. His research on Internal medicine often connects related topics like Gastroenterology. His Cohort study research also works with subjects such as
His study in Confidence interval is interdisciplinary in nature, drawing from both Odds ratio and Physiologically based pharmacokinetic modelling. Viral load is a subfield of Immunology that Manuel Battegay explores. His Epidemiology research incorporates elements of Virology and Environmental health.
The scientist’s investigation covers issues in Internal medicine, Pharmacokinetics, Severe acute respiratory syndrome coronavirus 2, Coronavirus disease 2019 and Confidence interval. His research integrates issues of Gastroenterology and Tuberculosis in his study of Internal medicine. Manuel Battegay combines subjects such as Virology, Public health surveillance, Contact tracing, Mass screening and Pandemic with his study of Severe acute respiratory syndrome coronavirus 2.
His studies examine the connections between Coronavirus disease 2019 and genetics, as well as such issues in 2019-20 coronavirus outbreak, with regards to Ritonavir, Drug, Lopinavir, Lopinavir/ritonavir and Mortality trends. The study incorporates disciplines such as Observational study, Proportional hazards model and Infection control in addition to Confidence interval. His Hazard ratio study which covers Incidence that intersects with Epidemiology.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Circulating microRNAs in sera correlate with soluble biomarkers of immune activation but do not predict mortality in ART treated individuals with HIV-1 infection : a case control study
Daniel D. Murray;Kazuo Suzuki;Matthew Law;Jonel Trebicka.
PLOS ONE (2015)
Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies
R Hogg;V Lima;J Sterne;S Grabar.
The Lancet (2008)
Genetic Variation in IL28B Is Associated With Chronic Hepatitis C and Treatment Failure: A Genome-Wide Association Study
Andri Rauch;Zoltán Kutalik;Zoltán Kutalik;Patrick Descombes;Tao Cai.
Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study.
Gilbert Greub;Bruno Ledergerber;M. Battegay;P. Grob.
The Lancet (2000)
Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients : a prospective cohort study
Bruno Ledergerber;Matthias Egger;Milos Opravil;Amalio Telenti.
The Lancet (1999)
Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. Swiss HIV Cohort Study.
Matthias Egger;Bernard Hirschel;Patrick Francioli;Philippe Sudre.
AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study.
Bruno Ledergerber;M. Egger;V. Erard;R. Weber.
Morbidity and Aging in HIV-Infected Persons: The Swiss HIV Cohort Study
Barbara Hasse;Bruno Ledergerber;Hansjakob Furrer;Manuel Battegay.
Clinical Infectious Diseases (2011)
CD4 T-Lymphocyte Recovery in Individuals With Advanced HIV-1 Infection Receiving Potent Antiretroviral Therapy for 4 Years: The Swiss HIV Cohort Study
Gilbert R. Kaufmann;Luc Perrin;Guiseppe Pantaleo;Milos Opravil.
JAMA Internal Medicine (2003)
Quantification of lymphocytic choriomeningitis virus with an immunological focus assay in 24- or 96-well plates.
Manuel Battegay;Sue Cooper;Alana Althage;Jürg Bänziger.
Journal of Virological Methods (1991)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: